Mark Rothera

Insider Reports History

Entity
Individual
Location
C/O Aegerion Pharmaceuticals, Inc., 101 Main Street, Suite 1850, Cambridge, MA
Signature
Daniel Chevallard, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Mark Rothera:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Viracta Therapeutics, Inc. President and CEO, Director Common Stock 100K $49.3K $0.49 Dec 1, 2023 Direct
Viracta Therapeutics, Inc. President and CEO, Director Stock Option (Right to Buy) 475K Mar 12, 2024 Direct

Insider Reports Filed by Mark Rothera

Symbol Company Period Transactions Value $ Form Type Date Filed Role
VIRX Viracta Therapeutics, Inc. Mar 12, 2024 1 $0 4 Mar 13, 2024 President and CEO, Director
VIRX Viracta Therapeutics, Inc. Nov 30, 2023 2 $49.4K 4 Dec 4, 2023 President and CEO, Director
VIRX Viracta Therapeutics, Inc. Mar 16, 2023 1 $0 4 Mar 17, 2023 President and CEO, Director
VIRX Viracta Therapeutics, Inc. Sep 19, 2022 1 $0 4 Sep 19, 2022 President and CEO, Director
VIRX Viracta Therapeutics, Inc. Sep 19, 2022 0 $0 3 Sep 19, 2022 President and CEO, Director